CureVac sues Moderna for patent infringement over COVID-19 vaccines
CureVac N.V. (NASDAQ:CVAC) Given Consensus Recommendation of “Hold” by Analysts
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
CureVac N.V. (CVAC) Shareholder/Analyst Call Prepared Remarks Transcript
CureVac Announces Voting Results of Extraordinary General Meeting
Brokerages Set CureVac N.V. (NASDAQ:CVAC) PT at $6.83
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates
CureVac: The Hidden Value Of The mRNA Wallet
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
GSK secures $370 million settlement and future royalties in CureVac mRNA patent dispute
CureVac settles patent dispute litigation with Pfizer and BioNTech
CureVac Announces Voting Results of General Meeting
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of CureVac N.V. (NASDAQ: CVAC)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders
Top Stock Movers Now: Oracle, Boeing, CureVac, and More
CureVac Stock Soars on BioNTech Buyout
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
BioNTech boosts cancer mRNA pipeline with CureVac acquisition
CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders
BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.
BioNTech to acquire CureVac in $1.25 billion all-stock deal
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE
CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
European Patent Office declares CureVac mRNA patent valid
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators
CureVac: Latest GBM Data Bodes Well For Next Program Check Point
2 Small-Cap Stocks Set to Shine in a Bull Market
Is the Options Market Predicting a Spike in CureVac (CVAC) Stock?
CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
CureVac to Present at the 12th International mRNA Health Conference
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents
CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
CureVac N.V. (CVAC) Expected to Beat Earnings Estimates: Should You Buy?
CureVac (CVAC) Upgraded to Buy: What Does It Mean for the Stock?